Table 3

Anti-topoisomerase I antibody-positive versus antibody-negative patients in systemic sclerosis cohort assessed by line immunoblot assay

Disease manifestation

Patients with disease manifestation

Anti-topoisomerase I

P value

Sensitivity (%)

Specificity (%)

Positive (n = 67)

Negative (n = 213)

Digital ulcers

112 (40.0%)

38 (56.7%)

74 (34.7%)

0.002

33.9

82.7

Lung fibrosis

98 (35.0%)

46 (68.6%)

52 (24.4%)

<0.0005

46.9

88.5

DLCO by a single breath

62.9 ± 20.8

72.9 ± 19.9

<0.0005

NA

NA

Mean FVC

81.1 ± 18.0

91.8 ± 18.7

<0.0005

NA

NA

Pulmonary arterial hypertension

60 (21.4%)

17 (25.4%)

43 (20.2%)

0.39

28.3

77.3

Contractures

162 (57.9%)

59 (88.1%)

113 (53.1%)

<0.0005

34.3

92.6

Renal involvement

56 (20.0%)

13 (19.4%)

43 (20.2%)

1

23.2

75.9

Renal crisis

16 (5.7%)

6 (9%)

10 (4.7%)

0.23

37.5

76.8

Cardiac involvement

114 (40.7%)

33 (49.2%)

81 (38.0%)

0.12

28.9

79.5

Conduction blocks

69 (24.6%)

25 (37.3%)

44 (20.7%)

0.009

36.2

80.1

Electrocardiogram changes

74 (26.4%)

27 (40.3%)

47 (22.1%)

0.007

36.5

80.4

mRSS

14.2 ± 10.2

5.57 ± 5.8

<0.0005

NA

NA

Raynaud's phenomenon

272 (97.1%)

67 (100%)

205 (96.2%)

0.2

24.6

100

Diffuse systemic sclerosis

96 (34.3%)

58 (86.6%)

38 (17.8%)

<0.0005

60.4

95.1

Mean disease activity

2.49

1.63

<0.0005

NA

NA

Data presented as n (%) or mean ± standard deviation. DLCO, predicted diffusion capacity; FVC, predicted forced vital capacity; mRSS, modified Rodnan skin score; NA, not applicable.

Hanke et al. Arthritis Research & Therapy 2009 11:R28   doi:10.1186/ar2622